Abivax Shares Surge 9.52% at Close Amid Acquisition Rumors

Significant Market Movements and Speculations

Abivax shares ended the trading session on Wednesday, December 10, at 115 euros, up 9.52% from the previous closing at 105 euros. The session was notably influenced by market rumors about a potential acquisition by American pharmaceutical giant Eli Lilly. The stock reached a session high of 20% before retracting, reflecting the intensity of speculative movements. Trading volumes reached 0.64% of the capital, significantly higher than in previous sessions. Over the week, the stock now shows a gain of 13.19%, reversing early December corrections and confirming the strength of the upward momentum. Over three months, the performance has reached 50.52%, while the annual increase has peaked at 1,341%, boosting the company's market capitalization to over 8 billion euros from 500 million euros in January. This remarkable revaluation positions Abivax as one of the top European performers of the year 2025, driven by the positive Phase 3 results of obefazimod, its drug candidate for the treatment of ulcerative colitis.

Favorable Environment for Biotechs and Clinical Success

The surge in the stock is part of a favorable environment for biotechs that have demonstrated the clinical efficacy of their drug candidates. Some sources estimate that treatments for chronic inflammatory bowel diseases could represent a potential global market of 30 billion dollars by 2030. The announcement in July 2025 of positive Phase 3 results had already caused the stock to jump more than 500% in a single day, triggering a fundamental revaluation of the company. The 44-week maintenance data, expected in the second quarter of 2026, will be the next critical step before the applications for marketing authorization with the FDA and the European Medicines Agency planned for the second half of 2026. The company raised 747.5 million dollars in July through a public offering on the Nasdaq, significantly strengthening its cash reserves to fund the final regulatory stages. This fundraising demonstrates institutional investors' confidence in the commercial potential of obefazimod, which could become a blockbuster in the segment of inflammatory bowel diseases.

Technical Analysis and Market Independence

Technically, the price of 115 euros is significantly above the 50-day moving average positioned at 89.27 euros, confirming a decidedly bullish underlying trend. The even more pronounced gap with the 200-day moving average at 41.83 euros illustrates the magnitude of the transformation since the beginning of the year. The difference of 47.44 euros between the 20-day and 200-day moving averages indicates an acceleration of momentum in the short term. The RSI at 57 remains in the neutral zone, suggesting that the stock still has room for progression before reaching an overbought zone, a technically favorable signal for the continuation of the movement. The Bollinger Bands frame the stock between a support at 87.55 euros and a resistance at 114.63 euros, with the price having crossed the upper boundary of this channel, indicating an acceleration of momentum. The major resistance identified at 111.80 euros has been clearly surpassed, paving the way for new historical highs. The MACD displays a negative histogram at -1.29, with a MACD line at 3.21 crossing below the signal line at 4.50, indicating a slight slowdown in momentum in the very short term, which does not invalidate the underlying trend. With a negative beta of -0.05, Abivax shows a total decorrelation with the CAC 40, explaining its ability to progress independently in an uncertain market environment. The one-month volatility of 18.82% reflects the significant fluctuations characteristic of biotechnological stocks in advanced clinical trial phases, amplified by acquisition speculations.